Skip to main content
Top

memo - Magazine of European Medical Oncology

Issue 2/2020

Content (25 Articles)

Circumnavigating the challenges of COVID-19 in oncology

Thorsten Fuereder, Eberhard Gunsilius, Rupert Bartsch, Wolfgang Hilbe

Epithelial ovarian cancer

Alexander Reinthaller

Open Access Breast Cancer short review

ESMO 2019: breast cancer

Rupert Bartsch

Open Access NSCLC short review

ESMO 2019—personal non-small lung cancer highlights

Lena Horvath, Andreas Pircher

Open Access Liposarcoma short review

The role of pathology in sarcoma

Bernadette Liegl-Atzwanger

Open Access Soft Tissue Sarcoma short review

Perioperative treatment of soft-tissue sarcoma

Christian Rothermundt

Liposarcoma short review

Metastatic sarcoma: tailored strategies for a heterogeneous disease

Massimiliano Grassi, Andrea Spagnoletti, Alberto Puccini

Open Access osteosarcoma short review

Therapy management in bone sarcoma

Martin Thaler, Ismail Khosravi

Open Access Ultrasound short review

Screening for ovarian cancer: is there still hope?

Stefanie Aust, Veronika Seebacher-Shariat

Open Access Ovarian Cancer short review

Ovarian cancer surgery

Richard Schwameis, Valentina Paspalj, Marlene Kranawetter, Stephan Polterauer

Open Access Ovarian Cancer review

PARP inhibitors in the treatment of ovarian cancer

Alain G. Zeimet, Verena Wieser, Katharina Knoll, Daniel Reimer, Christian Marth

Open Access Solid Tumor short review

Current state and perspectives of checkpoint inhibitors in ovarian cancer treatment

Thomas Bartl, Valentina Paspalj, Stephan Polterauer, Christoph Grimm

Open Access Computed Tomography short review

Thermal ablation—an option in curative treatment of HCC

Daniel Putzer, Peter Schullian, Gernot Eberle, Reto Josef Bale

Open Access Splenectomy original report

PLATON: use of romiplostim to treat chronic primary immune thrombocytopenia

Georgi Mihaylov, Barbara Skopec, Zuzana Sninska, Nikolai Tzvetkov, Olga Cerna, Vladlen Ivanushkin, Daniela Niepel, Katja Björklöf, Peter Černelč

Different CALR mutation subtypes in essential thrombocythemia and primary myelofibrosis patients without JAK2 mutation

Layla M. Saleh, Reem Algamal, Hanaa Abd Elmasseh, Emily Barber, Hasan Abdel-ghaffar

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine